So BTK inhibitor in combination with the BCL2 inhibitor, such as venetoclax, are showing promise in increasing the complete response rate and progression-free survival. And those are looking very promising from the SYMPATICO trial. And there are newer generations of similar trials that are ongoing. Hopefully, it may show the same thing. These are suggesting that we are able to use a combination, but I have to clarify that as of now, we don’t have an approved regimen of this sort...
So BTK inhibitor in combination with the BCL2 inhibitor, such as venetoclax, are showing promise in increasing the complete response rate and progression-free survival. And those are looking very promising from the SYMPATICO trial. And there are newer generations of similar trials that are ongoing. Hopefully, it may show the same thing. These are suggesting that we are able to use a combination, but I have to clarify that as of now, we don’t have an approved regimen of this sort. But in terms of balancing the toxicity and the efficacy data, I think the efficacy in terms of PFS increases is very notable. So if approved, I would be very comfortable using that regimen. Even now in standard care practice, off-label use, we sometimes do use that just because of the added benefit of the two agents. If we use BCL2 inhibitor as a single agent after BTK inhibitor, the efficacy is typically limited. I think by combining them, we probably can get a longer PFS by using them sequentially. Now, the toxicity is real because if we use the two agents together, I think the cytopenia risk is higher. Consequentially, then you probably will deal with a higher risk of infection. So we have to monitor patients closely when we use the combination. But I think that managing toxicity will not really discourage me from using the combination for the appropriate patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
